MX2010002477A - Perharidinas como inhibidores de cdk. - Google Patents

Perharidinas como inhibidores de cdk.

Info

Publication number
MX2010002477A
MX2010002477A MX2010002477A MX2010002477A MX2010002477A MX 2010002477 A MX2010002477 A MX 2010002477A MX 2010002477 A MX2010002477 A MX 2010002477A MX 2010002477 A MX2010002477 A MX 2010002477A MX 2010002477 A MX2010002477 A MX 2010002477A
Authority
MX
Mexico
Prior art keywords
pyridines
imidazo
perharidines
tetrasubstituted
trisubstituted
Prior art date
Application number
MX2010002477A
Other languages
English (en)
Spanish (es)
Inventor
Laurent Meijer
Karima Bettayeb
Herve Galons
Luc Demange
Nassima Oumata
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Publication of MX2010002477A publication Critical patent/MX2010002477A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2010002477A 2007-09-12 2008-09-12 Perharidinas como inhibidores de cdk. MX2010002477A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2007/003655 WO2009034411A1 (en) 2007-09-12 2007-09-12 Perharidines as cdk inhibitors
PCT/IB2008/003106 WO2009034475A2 (en) 2007-09-12 2008-09-12 Perharidines as cdk inhibitors

Publications (1)

Publication Number Publication Date
MX2010002477A true MX2010002477A (es) 2010-08-09

Family

ID=39773126

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002477A MX2010002477A (es) 2007-09-12 2008-09-12 Perharidinas como inhibidores de cdk.

Country Status (10)

Country Link
US (1) US8450342B2 (enExample)
EP (1) EP2185557A2 (enExample)
JP (1) JP2010539155A (enExample)
KR (1) KR20100075907A (enExample)
CN (1) CN101809020A (enExample)
BR (1) BRPI0816799A2 (enExample)
CA (1) CA2699040A1 (enExample)
MX (1) MX2010002477A (enExample)
RU (1) RU2498984C2 (enExample)
WO (2) WO2009034411A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013059634A1 (en) 2011-10-20 2013-04-25 The Regents Of The University Of California Use of cdk9 inhibitors to reduce cartilage degradation
CN105481858B (zh) * 2014-10-11 2019-05-17 上海医药集团股份有限公司 一种含氮稠杂环化合物、其制备方法、组合物及应用
SMT202500028T1 (it) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Terapie combinate
CN111217814B (zh) * 2018-11-26 2022-08-26 天津科技大学 一类联哌啶衍生物及其作为抗肿瘤药物的应用
US20230115907A1 (en) 2019-12-20 2023-04-13 Evopoint Biosciences Co., Ltd. Heterocyclic compound and pharmaceutical composition, preparation method, intermediate and use thereof
GB202108572D0 (en) * 2021-06-16 2021-07-28 Carrick Therapeutics Ltd Therapeutic compounds and their use
CN115104576A (zh) * 2022-07-12 2022-09-27 河北医科大学 Cdk5调控eEF2在糖尿病肾病防治中的操作方法
CN118598874A (zh) * 2024-05-21 2024-09-06 江南大学 一种取代的9h嘌呤类化合物、药物组合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU566842A1 (ru) * 1976-01-06 1977-07-30 Донецкое Отделение Физико-Органической Химии Института Физической Химии Им.Л.В.Писаржевского Ан Украинской Сср Способ получени замещенных имидазопиридинов
AU7738000A (en) * 1999-09-30 2001-04-30 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
UA74593C2 (en) * 2000-12-08 2006-01-16 3M Innovative Properties Co Substituted imidazopyridines
EP1352910A1 (en) * 2002-04-10 2003-10-15 Grünenthal GmbH New analogs of nitrobenzylthioinosine
CA2491680C (en) * 2002-07-02 2012-04-17 Southern Research Institute Inhibitors of ftsz and uses thereof
CA2576159A1 (en) * 2004-08-27 2006-03-02 Cyclacel Limited Purine and pyrimidine cdk inhibitors and their use for the treatment of autoimmune diseases
TW200616624A (en) * 2004-09-09 2006-06-01 Solvay Pharm Bv 2-substituted-1-deaza purine derivatives with adenosine receptor modulating activity
EP1824850A2 (en) * 2004-12-09 2007-08-29 Nycomed GmbH SUBSTITUTED IMIDAZO[4,5-b]PYRIDINES AS INHIBITORS OF GASTRIC ACID SECRETION

Also Published As

Publication number Publication date
KR20100075907A (ko) 2010-07-05
CN101809020A (zh) 2010-08-18
RU2498984C2 (ru) 2013-11-20
WO2009034411A1 (en) 2009-03-19
EP2185557A2 (en) 2010-05-19
US20100280065A1 (en) 2010-11-04
RU2010108507A (ru) 2011-10-20
CA2699040A1 (en) 2009-03-19
WO2009034475A3 (en) 2009-08-13
WO2009034475A2 (en) 2009-03-19
BRPI0816799A2 (pt) 2015-03-03
US8450342B2 (en) 2013-05-28
JP2010539155A (ja) 2010-12-16

Similar Documents

Publication Publication Date Title
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
WO2008046581A3 (de) Substituierte tetrahydropyrrolopyrazin-verbindungen als inhibitoren der monoaminwiederaufnahme und deren verwendung in arzeimitteln
PL1891004T3 (pl) Pentafluorosulfanylo-podstawiony związek i jego zastosowanie do wytwarzania środków leczniczych
IL219164A0 (en) A process for the preparation of optically active chiral amines
WO2011138281A3 (de) Verfahren zur herstellung von dithiin-tetracarboxy-diimiden
MX2007008790A (es) Pirazolo piridinas sustituidas, composiciones que las contienen, metodo de produccion de las mismas, y su uso.
ATE527266T1 (de) Herstellungsverfahren für asenapin und in diesem verfahren verwendete zwischenprodukte
MX2009003382A (es) Derivados de sulfonamidas sustituidos.
WO2009034475A3 (en) Perharidines as cdk inhibitors
WO2010102778A3 (de) Substituierte 3-aminoisoxazolopyridine als kcnq2/3 modulatoren
EA200702329A1 (ru) Замещенные пирролпиридины, содержащие их композиции, способ получения и применение
NZ586187A (en) Processes for the synthesis of sinomenine derivatives and their intermediate
TN2010000219A1 (en) 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents
MY146084A (en) Benzyl amines, a process for their production and their use as anti-inflammatory agents
WO2008140641A3 (en) Pure paliperidone and processes for preparing thereof
MX2010010597A (es) Procesos para la preparacion de derivados de dioxina benzofusionados.
WO2008053334A3 (en) An improved process for preparing rosuvastatin calcium
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
WO2008131946A3 (de) Substituierte amid-derivate
GEP20135747B (en) Method of benzonorbornenes production
WO2008116056A3 (en) NOVEL METHODS FOR PRODUCTION OF 5-EPI-β-VETIVONE, 2-ISOPROPYL-6,10-DIMETHYL-SPIRO[4.5]DECA-2,6-DIEN-8-ONE, AND 2-ISOPROPYL-6,10-DIMETHYL-SPIRO[4.5]DECA-1,6-DIEN-8-ONE
WO2008021346A3 (en) Pure paliperidone and processes for preparing thereof
MX2010002506A (es) Compuestos de nicotinamida sustituidos y uso de estos en medicamentos.
WO2009062659A3 (en) Polymorphs of enantiopure erdosteine
WO2008094617A3 (en) Crystalline forms of deferasirox

Legal Events

Date Code Title Description
FG Grant or registration